natgillin/translations-raw huggingface dataset:
Dupilumab trough concentrations were lower in subjects with higher body weight with no meaningful impact on efficacy. 
Najnižja koncentracija dupilumaba je bila pri preiskovancih z večjo telesno maso nižja, vendar to ni pomembno vplivalo na učinkovitost.
Time out of refrigeration should not exceed a maximum of 14 days at temperature below 25 °C. 
Čas, ko je zdravilo zunaj hladilnika, ne sme biti daljši od 14 dni pri temperaturi do 25 °C.
Median % reduction in daily OCS dose from baseline 
Mediani % zmanjšanja dnevnega odmerka PKS od izhodišča
respondersc, d 
% odzivnihc, d
Dupilumab should not be used to treat acute bronchospasm or status asthmaticus. 
Dupilumaba se ne sme uporabljati za zdravljenje akutnega bronhospazma ali astmatičnega statusa.
N Responder rate % 
N Delež odziva %
SOLO 2 at Week 16 
SOLO 2 po 16 tednih
In CHRONOS, efficacy was also evaluated at week 52. 
V študiji CHRONOS so učinkovitost ocenili tudi po
Dupixent is unlikely to influence your ability to drive and use machines. 
Ni verjetno, da bi zdravilo Dupixent vplivalo na vašo sposobnost upravljanja vozil in strojev.
Lift your thumb to release the plunger rod until the needle is covered by the needle shield and then remove the syringe from the injection site. 
Dvignite palec, da boste sprostili bat, dokler igla ni pokrita s ščitnikom igle, nato brizgo odstranite z mesta injiciranja.
A patient may self-inject dupilumab or the patient's caregiver may administer dupilumab if their healthcare professional determines that this is appropriate. 
Bolnik si lahko sam injicira dupilumab, ali mu ga injicira njegov negovalec, če zdravnik presodi, da je to primerno.
Eosinophil counts declined to near baseline levels during study treatment. 
Število eozinofilcev se je med raziskovanim zdravljenjem zmanjšalo na skoraj izhodiščno raven.
Topical calcineurin inhibitors may be used, but should be reserved for problem areas only, such as the face, neck, intertriginous and genital areas. 
Uporabiti je mogoče lokalne zaviralce kalcinevrina, ki pa morajo biti pridržani za težavne predele, kot so obraz, vrat, intertriginozni predeli in predel spolovil.
Proper training should be provided to patients and/or caregivers on the preparation and administration of dupilumab prior to use according to the Instructions for Use (IFU) section in the package leaflet. 
Bolnikom in/ali negovalcem je treba pred uporabo zagotoviti ustrezno usposabljanje o pripravi in dajanju dupilumaba v skladu s poglavjem "Navodila za uporabo" v navodilu za uporabo zdravila.
Patients continued to receive their existing asthma medicine during the study; however their OCS dose was reduced every 4 weeks during the OCS reduction phase (week 4-20), as long as asthma control was maintained. 
Bolniki so med študijo še naprej uporabljali svoje siceršnje zdravilo za astmo, toda odmerek PKS so jim med obdobjem zmanjševanja PKS (od 4. do 20. tedna) zmanjševali na 4 tedne, dokler je ostajala astma urejena.
The primary endpoint was the proportion of patients with EASI-75 at week 16. 
Primarni opazovani dogodek je bil delež bolnikov z EASI-75 16. teden.
Clinical efficacy and safety in atopic dermatitis 
Klinična učinkovitost in varnost pri atopijskem dermatitisu
No adverse interactions between either of the non-live vaccines and dupilumab were noted in the study. 
V študiji niso ugotovili neželenega medsebojnega delovanja med nobenim od obeh neživih cepiv in dupilumabom.
Keep holding the pre-filled pen firmly against your skin. 
Še naprej držite napolnjeni injekcijski peresnik trdno na koži.
SOLO 1 at Week 16 
SOLO 1 po 16 tednih
Dupilumab inhibits IL-4 signaling via the Type I receptor (IL-4Rα/γc), and both IL-4 and IL-13 signaling through the Type II receptor (IL-4Rα/IL-13Rα). 
Dupilumab zavira signalizacijo z IL-4 preko receptorjev tipa I (IL-4Rα/γc), signalizacijo tako z IL-4 kot z IL-13 pa preko receptorjev tipa II (IL-4Rα/IL-13Rα).
Dupilumab is a monoclonal antibody (a type of specialised protein) that blocks the action of proteins called IL-4 and IL-13. 
Dupilumab je monoklonsko protitelo (vrsta specializiranih beljakovin), ki preprečuje delovanje beljakovin IL-4 in IL-13.
Dupixent has also been shown to improve symptoms of pain, anxiety, and depression associated with atopic dermatitis. 
Dokazano je, da zdravilo Dupixent izboljša tudi bolečine, tesnobnost (anksioznost) in depresijo, povezane z atopijskim dermatitisom.
Key Secondary Endpoints 
Ključni sekundarni opazovani dogodki
If you already have a parasitic infection it should be treated before you start treatment with Dupixent. 
Če že imate kakšno zajedavsko okužbo, jo je treba zdraviti, preden začnete zdravljenje z zdravilom Dupixent.
The European Medicines Agency has deferred the obligation to submit the results of studies with dupilumab in one or more subset of the paediatric population in atopic dermatitis and asthma (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z dupilumabom pri atopijskem dermatitisu in astmi za eno ali več podskupin pediatrične populacije (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
You must look out for signs of these conditions (i.e. breathing problems, swelling of the face, mouth, and tongue, fainting, dizziness, feeling lightheaded (low blood pressure), fever, general ill feeling, swollen lymph nodes, hives, itching, joint pain, skin rash) while you are taking Dupixent. 
Med uporabo zdravila Dupixent morate biti pozorni na znake takšnih reakcij (npr. na težave z dihanjem, otekanje obraza, ust in jezika, omedlevico, omotico, občutek vrtoglavosti (nizek krvni pritisk) zvišano telesno temperaturo, splošno slabo počutje, otekle bezgavke, koprivnico (urtikarijo), srbenje, bolečine v sklepih, izpuščaj na koži).
Check if the liquid is clear and colourless to pale yellow. 
Preverite, da je tekočina bistra in brezbarvna do bledo rumena.
Dupilumab may influence the immune response against helminth infections by inhibiting IL-4/IL-13 signaling. 
Dupilumab lahko vpliva na imunski odziv proti okužbam s helminti, ker zavira signalizacijo IL-4/IL-13.
In addition, there was one patient with serum sickness and one with serum sickness-like reaction (< 0.1 %) associated with high ADA titers (see section 4.4). 
Poleg tega je imel v povezavi z visokim titrom ADA en bolnik serumsko bolezen in en bolnik serumski bolezni podobno reakcijo (< 0,1 %) (glejte poglavje 4.4).
Placebo 127 0.09 (4.36) QUEST study 
Placebo 127 0,09 (4,36) Študija QUEST Dupilumab
Very limited data are available in patients with severe renal impairment. 
Podatkov o bolnikih s hudo okvaro ledvic je zelo malo.
Primary and secondary endpoints for the 52 week SOLO CONTINUE study are summarized in table 7. 
Primarni in sekundarni opazovani dogodki 52-tedenske študije SOLO CONTINUE so povzeti v preglednici 7.
The long-term efficacy of dupilumab in adolescent patients with moderate-to-severe AD who had participated in previous clinical trials of dupilumab was assessed in open-label extension study (AD1434). 
Dolgoročno učinkovitost dupilumaba pri mladostnikih z zmernim do hudim AD, ki so sodelovali v predhodnih kliničnih preskušanjih dupilumaba, so ocenili v odprti podaljšani študiji (AD-1434).
Lay the pre-filled pen on a flat surface and let it naturally warm up at room temperature (less than 25ºC) for at least 30 minutes. 
Položite napolnjeni injekcijski peresnik na ravno površino in pustite, da se naravno segreje na sobno temperaturo (manj kot 25 °C); pustite ga vsaj 30 minut.
Patients receiving concomitant oral corticosteroids may reduce their steroid dose once clinical improvement with dupilumab has occurred (see section 5.1). 
Bolniki, ki sočasno prejemajo peroralne kortikosteroide, lahko zmanjšajo odmerek steroidov, ko se z dupilumabom pojavi klinično izboljšanje (glejte poglavje 5.1).
Dupixent may be used with eczema medicines that you apply to the skin or it may be used on its own. 
Zdravilo Dupixent se lahko uporablja skupaj z zdravili za ekcem, ki jih nanesete na kožo, ali pa se uporablja samo.
Using Dupixent for atopic dermatitis (atopic eczema) can improve the condition of your skin and reduce itching. 
Uporaba zdravila Dupixent za atopijski dermatitis (atopijski ekcem) lahko izboljša stanja kože in zmanjša srbenje.
Treatment effects in subgroups (weight, age, gender, race, and background treatment, including immunosuppressants) in CHRONOS were consistent with the results in the overall study population. 
Terapevtski učinki so se v podskupinah (telesna masa, starost, spol, rasa in osnovno zdravljenje, vključno z imunosupresivi) v študiji CHRONOS skladali z rezultati v celotni populaciji študije.
Tell your doctor or pharmacist - if you are using, have recently used or might use any other medicines. 
- če uporabljate, ste pred kratkim uporabljali ali pa boste morda začeli uporabljati katero koli drugo zdravilo.
VENTURE evaluated the effect of dupilumab on reducing the use of maintenance oral corticosteroids. 
Študija VENTURE je ovrednotila učinek dupilumaba na zmanjšanje uporabe vzdrževalnih peroralnih kortikosteroidov (PKS).
Inject Dupixent yourself only after you have been trained by your doctor or nurse. 
Zdravilo Dupixent si smete injicirati sami šele potem, ko sta vas zdravnik ali medicinska sestra tega naučila.
Animal studies showed no impairment of fertility (see section 5.3). 
Študije na živalih niso pokazale okvare plodnosti (glejte poglavje 5.3).
A volume of distribution for dupilumab of approximately 4.6 L was estimated by population PK analysis, indicating that dupilumab is distributed primarily in the vascular system. 
S populacijsko FK analizo ocenjeni volumen porazdelitve dupilumaba je bil približno 4,6 l; to kaže, da se dupilumab v prvi vrsti porazdeli v ožilju.
Placebo + TCS 
Placebo + LKS
Due to nonlinear clearance, dupilumab exposure, as measured by area under the concentration-time curve, increases with dose in a greater than proportional manner following single SC doses from 75600 mg. 
Zaradi nelinearnega očistka se izpostavljenost dupilumabu, merjena s površino pod krivuljo koncentracije po času, po enkratnih subkutanih odmerkih od 75 do 600 mg povečuje bolj kot sorazmerno odmerku.
How to store Dupixent 6. 
Shranjevanje zdravila Dupixent 6.
The most common adverse reaction was injection site erythema. 
Najpogostejši neželeni učinek je bil eritem na mestu injiciranja.
The safety of dupilumab was evaluated in four randomized, double-blind, placebo-controlled studies and one dose-ranging study in patients with moderate-to-severe atopic dermatitis. 
Varnost dupilumaba so ocenili v štirih randomiziranih, dvojno slepih, s placebom kontroliranih študijah in v eni študiji razpona odmerkov pri bolnikih z zmernim do hudim atopijskim dermatitisom.
Remove the syringe from the carton by holding the middle of the syringe body. 
Vzemite brizgo iz škatle tako, da jo primete na sredi telesa brizge.
The primary endpoint was the percent reduction in oral corticosteroid dose assessed in the overall population, based on a comparison of the oral corticosteroid dose at weeks 20 to 24 that maintained asthma control with the previously optimized (at baseline) oral corticosteroid dose. 
Primarni opazovani dogodek je bil odstotek zmanjšanja odmerka peroralnega kortikosteroida, ocenjen v celotni populaciji na podlagi primerjave odmerka peroralnega kortikosteroida od 20. do 24. tedna, ki je ohranjal urejenost astme, s predhodno (izhodiščno) optimiziranim odmerkom peroralnega kortikosteroida.
Do not rub your skin after the injection. 
Ne drgnite kože po injiciranju.
A. Check expiration date 
A. Preverite datum izteka roka uporabnosti
Of the 1,472 patients with atopic dermatitis exposed to dupilumab in a phase 2 dose-ranging study or phase 3 placebo-controlled studies, a total of 67 were 65 years or older. 
Od 1.472 bolnikov z atopijskim dermatitisom, ki so bili dupilumabu izpostavljeni v študiji 2. faze razpona odmerkov ali v študijah 3. faze, kontroliranih s placebom, je bilo skupno 67 bolnikov starih 65 let ali več.
In this study, the mean age was 14.5 years, the median weight was 59.4 kg, 41.0 % were female, 62.5% were White, 15.1% were Asian, and 12.0% were Black. 
V tej študiji je bila povprečna starost 14,5 leta, mediana telesna masa 59,4 kg, 41 % oseb je bilo ženskega spola, 62,5 % belcev, 15,1 % Azijcev in 12,0 % črncev.
If you have asthma and are taking asthma medicines, do not change or stop your asthma medicine without talking to your doctor. 
Če imate astmo in uporabljate zdravila za astmo, zdravil za astmo ne spreminjajte in jih ne prenehajte uporabljati, ne da bi se posvetovali z zdravnikom.
Do not put the needle cap back on. 
Ne nameščajte pokrovčka igle nazaj nanjo.
Treatment effects in subgroups (weight, age, gender, race, and background treatment, including immunosuppressants) in SOLO 1 and SOLO 2 were consistent with the results in the overall study population. 
Terapevtski učinki so se v podskupinah (telesna masa, starost, spol, rasa in osnovno zdravljenje, vključno z imunosupresivi) v študijah SOLO 1 in SOLO 2 skladali z rezultati v celotni populaciji študij.
Dupilumab should not be used to treat acute asthma symptoms or acute exacerbations. 
Dupilumaba se ne sme uporabljati za zdravljenje akutnih simptomov astme ali akutnih poslabšanj astme.
Do not use the pre-filled pen if the expiration date has passed. 
Ne uporabite napolnjenega injekcijskega peresnika, če je ta datum že potekel.
Effects on lung function, on oral steroid and exacerbation reduction were similar irrespective of baseline levels of type 2 inflammatory biomarkers (e.g. blood eosinophils, FeNO). 
Učinki na delovanje pljuč, peroralni steroid in zmanjšanje poslabšanj so bili podobni ne glede na izhodiščno raven bioloških označevalcev vnetja tipa 2 (npr. eozinofilcev v krvi,
Always keep the container out of the reach of children. 
Vsebnik vedno shranjujte nedosegljiv otrokom.
Table 7: Results of the primary and secondary endpoints in SOLO CONTINUE study Placebo 
Preglednica 7: Rezultati primarnih in sekundarnih opazovanih dogodkov v študiji SOLO CONTINUE
Asthma treatment guidelines define type 2 inflammation as eosinophilia ≥ 150 cells/mcL and/or FeNO ≥ 20 ppb. 
Smernice za zdravljenje astme opredeljujejo vnetje tipa 2 kot eozinofilijo ≥ 150 celic/mcl in/ali diNO ≥ 20 ppb.
All Severe Exacerbations DRI12544 study Dupilumab 
Vsa huda poslabšanja Študija DRI12544 Dupilumab2
You and your doctor should decide if you will breast-feed or use Dupixent. 
Skupaj z zdravnikom se morate odločiti, ali boste dojili ali boste uporabljali zdravilo Dupixent.
Very common Injection site reactions 
Zelo pogosti reakcije na mestu injiciranja
Patients received dupilumab or placebo with concomitant use of TCS starting at baseline using a standardized regimen. 
Prejemanje dupilumaba ali placeba s sočasnim LKS se je začelo ob izhodišču z uporabo standardizirane sheme.
If you need to permanently remove the carton from the refrigerator, write down the date of removal in the space provided on the outer carton, and use Dupixent within 14 days. 
Če morate škatlo za stalno vzeti iz hladilnika, zapišite datum, ko ste jo vzeli iz hladilnika, na temu namenjen prostor na škatli ter zdravilo Dupixent porabite v 14 dneh.
After removing the 300 mg pre-filled syringe from the refrigerator, it should be allowed to reach room temperature by waiting for 45 min before injecting Dupixent. 
Potem, ko je 300 mg napolnjena injekcijska brizga vzeta iz hladilnika, je treba pustiti, da doseže sobno temperaturo, in sicer tako, da se jo pusti na sobni temperaturi 45 minut pred injiciranjem zdravila Dupixent.
• general ill feeling 
• splošno slabo počutje
Eligible patients enrolled into the three studies had previous inadequate response to topical medication. 
Primerni bolniki, vključeni v omenjene tri študije, se predhodno niso zadostno odzvali na lokalna zdravila.
Population PK analysis did not identify mild or moderate renal impairment as having a clinically meaningful influence on the systemic exposure of dupilumab. 
Populacijska FK analiza ni ugotovila, da bi blaga ali zmerna okvara ledvic klinično pomembno vplivala na sistemsko izpostavljenost dupilumabu.
The safety and benefits of Dupixent are not yet known in children with asthma below the age of 12. 
Varnost in koristi zdravila Dupixent še niso znane pri otrocih z astmo, mlajših od 12 let.
The demographics and baseline characteristics of these 3 studies are provided in Table 5 below. 
Demografske in izhodiščne značilnosti vseh treh študij so prikazane spodaj v preglednici 5.
Treatment-emergent eosinophilia (≥ 5,000 cells/mcL) was reported in < 2 % of dupilumab-treated patients and < 0.5 % in placebo-treated patients. 
Med zdravljenjem nastalo eozinofilijo (≥ 5.000 celic/mcl) so zabeležili pri < 2 % bolnikov, zdravljenih z dupilumabom, in pri < 0,5 % bolnikov, ki so prejemali placebo.
Less than 0.4 % of patients exhibited high titer ADA responses associated with reduced exposure and efficacy. 
Odziv z visokim titrom ADA, povezan z zmanjšanjem izpostavljenosti in učinkovitosti, je imelo manj kot 0,4 % bolnikov.
The safety and benefits of Dupixent are not yet known in children and adolescents with atopic dermatitis below the age of 12. 
Varnost in koristi zdravila Dupixent še niso znane pri otrocih in mladostnikih z atopijskim dermatitisom, mlajših od 12 let.
400 mg (two 200 mg injections) 
400 mg (dve 200-mg injekciji)
The pharmacokinetics of dupilumab in paediatric patients (< 12 years of age) with atopic dermatitis has not been studied. 
Pediatrični bolniki Farmakokinetika dupilumaba pri pediatričnih bolnikih (mlajših od 12 let) z atopijskim dermatitisom ni bila raziskana.
What Dupixent is and what it is used for 
Kaj je zdravilo Dupixent in za kaj ga uporabljamo
Patients randomized IGA 0 or 1c, % respondersd 
Randomizirani bolniki IGA 0 ali 1c, % odzivnihd
The pharmacokinetics of dupilumab is similar in patients with atopic dermatitis and asthma. 
Farmakokinetila dupilumaba je podobna tako pri bolnikih z atopijskim dermatitisom kot pri bolnikih z astmo.
A total of 325 patients were enrolled, with 210 patients who were previously exposed to ciclosporin and 115 patients who have never been exposed to ciclosporin because ciclosporin treatment was medically inadvisable. 
Vključenih je bilo skupno 325 bolnikov; 210 bolnikov je predhodno že prejemalo ciklosporin, 115
CDLQI, (≥6-point improvement), % responders POEM, LS mean change from baseline (+/- SE) 
CDLQI, (izboljšanje za ≥ 6 točk), % odzivnih POEM, povprečna % sprememba od izhodišča po mNK (+- SN)
Patients treated with dupilumab who develop conjunctivitis that does not resolve following standard treatment should undergo ophthalmological examination (section 4.8). 
Bolniki, zdravljeni z dupilumabom, ki se jim pojavi konjunktivitis in jim ne izgine po običajnem zdravljenju, morajo opraviti pregled pri oftalmologu (poglavje 4.8).
Immune responses to TdaP vaccine and meningococcal polysaccharide vaccine were assessed, see section 4.5. 
Imunske odzive na cepivo proti davici, tetanusu in oslovskemu kašlju (brezcelično) ter na meningokokno polisaharidno cepivo so ocenili, glejte poglavje 4.5.
In a clinical study of AD patients, the effects of dupilumab on the pharmacokinetics (PK) of CYP substrates were evaluated. 
V klinični študiji bolnikov z AD so ocenili učinke dupilumaba na farmakokinetiko (FK) substratov CYP.
PHARMACEUTICAL PARTICULARS 6.1 List of excipients arginine hydrochloride histidine polysorbate 80 sodium acetate trihydrate glacial acetic acid sucrose water for injections 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi argininijev klorid histidin polisorbat 80 natrijev acetat trihidrat ledocetna kislina saharoza voda za injekcije
Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity (including safety pharmacology endpoints) and toxicity to reproduction and development. 
Predklinični podatki na osnovi običajnih študij toksičnosti ponavljajočih se odmerkov (vključno z opazovanimi dogodki varnostne farmakologije) in toksičnosti za reprodukcijo in razvoj ne kažejo posebnega tveganja za človeka.
• Do not press or touch the orange needle cover with your fingers. 
• Ne pritiskajte in ne dotikajte se s prsti oranžnega pokrovčka igle.
The pre-filled syringe or the pre-filled pen should not be exposed to heat or direct sunlight and should not be shaken. 
Napolnjene injekcijske brizge ali napolnjenega injekcijskega peresnika se ne sme izpostavljati vročini ali neposredni sončni svetlobi in se je ne sme pretresati.
600 mg (two 300 mg injections) 
600 mg (dve 300-mg injekciji)
SANOFI WINTHROP INDUSTRIE 1051 Boulevard Industriel, 76580 LE TRAIT, FRANCE 
SANOFI WINTHROP INDUSTRIE 1051 Boulevard Industriel, 76580 LE TRAIT, FRANCIJA
Prepare the injection site 
Pripravite mesto injiciranja.
Step 2: Prepare 
2. korak: Pripravite vse potrebno
Conjunctivitis related events 
S konjunktivitisom povezani dogodki
Do not press or touch the orange needle cover with your fingers. 
Ne pritiskajte in ne dotikajte se s prsti oranžnega pokrovčka igle.
Check with your doctor if you have diarrhea, gas, upset stomach, greasy stools, and dehydration which could be a sign of a parasitic infection. 
Posvetujte se z zdravnikom, če imate drisko, vetrove, razdražen želodec, mastno blato ali dehidracijo (ste izsušeni): to so lahko znaki okužbe z zajedavci.
Adolescents 
Mladostniki
In atopic dermatitis clinical trials, treatment with dupilumab was associated with decreases from baseline in concentrations of type 2 immunity biomarkers, such as thymus and activation-regulated chemokine (TARC/CCL17), total serum IgE and allergen-specific IgE in serum. 
V kliničnih preskušanjih pri atopijskem dermatitisu je zdravljenje z dupilumabom v primerjavi z izhodiščem zmanjšalo koncentracijo bioloških označevalcev imunosti tipa 2, kot npr. timusni in z aktivacijo regulirani kemokin (TARC/CCL17), celokupne IgE v serumu in za alergen specifične IgE v serumu.
Very rarely, Dupixent can cause serious side effects, including allergic (hypersensitivity) reactions and anaphylactic reaction. 
Zelo redko lahko zdravilo Dupixent povzroči resne neželene učinke, vključno z alergijskimi (preobčutljivostnimi) reakcijami ter anafilaktično reakcijo.
• Dispose of the pre-filled pens, (needle inside), and yellow caps in a puncture resistant container right away after use. 
• Napolnjene injekcijske peresnike (z iglo v njih) in rumene pokrovčke tako po uporabi zavrzite v vsebnik, odporen proti prebadanju.
What Dupixent looks like and contents of the pack 
Izgled zdravila Dupixent in vsebina pakiranja
The recommended dose of dupilumab for adults and adolescents (12 years of age and older) is: 
Začetni odmerek dupilumaba za odrasle in mladostnike (stare 12 let in več) je:
The demographics and baseline characteristics of these 3 studies are provided in Table 11 below. 
Demografske in izhodiščne značilnosti vseh treh študij so prikazane spodaj v preglednici 11.
To evaluate maintenance and durability of response, subjects treated with dupilumab for 16 weeks in SOLO 1 and SOLO 2 studies who achieved IGA 0 or 1 or EASI-75 were re-randomized in SOLO CONTINUE study to an additional 36-week treatment of dupilumab or placebo, for a cumulative 52week study treatment. 
Za oceno vzdrževanja in trajnosti odziva so preiskovance, ki so bili v študijah SOLO 1 in SOLO 2 16 tednov zdravljeni z dupilumabomin so dosegli IGA 0 ali 1 ali EASI-75, v študiji SOLO CONTINUE ponovno randomizirali na dodatnih 36 tednov prejemanja dupilumaba ali placeba, tako da je raziskovano zdravljenje kumulativno trajalo 52 tednov.
Table 11: Demographics and Baseline Characteristics of Asthma Trials 
Preglednica 11: Demografske in izhodiščne značilnosti v preskušanjih pri astmi
If the solution is cloudy, discoloured or contains visible particulate matter, the solution should not be used. 
Če je raztopina motna, spremenjene barve ali vsebuje vidne delce, se je ne sme uporabiti.
Very common Common 
Zelo pogosti Pogosti
Do not dispose of (throw away) pre-filled pens (needle inside), and yellow caps in your household trash. 
Napolnjenih injekcijskih peresnikov (z iglo v njih) in rumenih pokrovčkov ne smete zavreči med gospodinjske odpadke.